HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 20, No 12, December 2016 – Medical Imaging Technology       » Climate Change Could Hurt Coffee, Help Banana Production       » Partnerships and Innovation: Shaping the Future of Healthcare in Asia Pacific       » Chugai's Novel Antibody Technologies Put Singapore at the Centre of Fight Against Disease       » NUS Scientists Discover the "Switch" that Makes Breast Cancer Cells Aggressive      
BIOBOARD - AUSTRALIA
Phylogica and Bio-Link collaborate to commercialize anti-inflammatory Phylomers
Phylogica Ltd, a leading Australian peptide drug discovery company, announced that it has entered an agreement with Bio-Link Australia Pty. Ltd., a specialist life sciences business development company, to commercialize a family of anti-inflammatory PhylomerÒ peptides for pharmaceutical use. Under the terms of the agreement, Bio-Link will work with Phylogica to monetize these assets through out-licensing or disposal of the Phylomer peptides to a pharmaceutical or biotechnology company.

The family of anti-inflammatory Phylomer peptides, including lead candidates PYC35, PYC36, PYC38 and PYC98, target the AP-1 pathway, which is a crucial mediator of inflammation in various diseases. The AP-1 pathway plays a critical role in neuronal cell death caused by stroke and traumatic brain injury, and lung inflammation resulting from acute respiratory distress syndrome (ARDS) and septic shock. The family of Phylomer peptides have demonstrated efficacy in multiple preclinical models for stroke, traumatic brain injury and ARDS.

Phylogica has developed a strong patent estate around this family of peptides. In addition to granted patents in Australia, the USA and Europe covering composition of matter of several of these peptides, a patent for their use in treatment of neuronal conditions has been granted in the USA. Phylogica has also recently been allowed a European patent, which covers formulations of these peptides for the treatment of ischemia.

The commercialization efforts of Phylogica and Bio-Link will be supported by a grant of $20,000 from the Western Australian government under the Innovation Vouchers Program (IVP). The IVP is part of the government's Translating Research Scheme with the objective to translate research into economic, social and environmental outcomes for industry, government and the community of Western Australia. The major aim of the IVP is to enable small-to-medium enterprises to have access to, and establish collaborative relationships with, research providers and/or specialist commercialization support services.

Dr. Paul Watt, Phylogica's Chief Executive Officer, commented on the news: “This non-dilutive grant income from the government has provided us with an opportunity to engage Bio-Link to support ongoing efforts to monetize our portfolio of Phylomer peptides targeting the AP-1 pathway. We believe that these unique peptides have substantial potential as drug candidates for multiple diseases and conditions with unmet medical need. The Bio-Link team comprises experienced industry executives with an excellent track record in securing partners or acquirers for biotech assets. We look forward to working with them to accelerate partnerships around these Phylomers, while Phylogica's management team maintains its focus on building the Company's drug discovery alliance activities.”

Paul Field, Bio-Link's Executive Chairman, said: “We are excited by the opportunity to work with Phylogica and to partner this family of AP-1 inhibitory peptides with companies seeking new potential therapies for stroke, traumatic brain injury and ARDS.”

Click here for the complete issue.

NEWS CRUNCH  
news Accuron Technologies' MedTech Division Invests into AWAK Technologies
news Philips introduces PerformanceBridge suite of operational performance improvement software and services for radiology departments
news Give a Gift that Will Last a Lifetime this Holiday Season with Smile Train
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2017
January:
Lungs & Respiratory System
February:
Cancer Research, Treatment/Technology
March:
Traditional Chinese Medicines
April:
Eye Care/ Eye Health
May:
The Piece of Your Mind - Brain Health/Science
June:
Featuring Biotech Start-Ups/Companies
July:
Food Science & Technology
August:
Diabetics Technology
September:
No. 1 Killer - Heart Diseases, Diagnosis and Treatment
October:
Skin Diseases/Allergic Reactions
November:
Diseases threatening our Children
December:
Liver Health & Treatment/Technology
Editorial calendar is subjected to changes.
– Editor: Carmen, Jia Wen Loh
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Carmen
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2016 World Scientific Publishing Co Pte Ltd  •  Privacy Policy